ALEC - Rasio kapitalisasi pasar marang pendapatan Alector Inc.
The current P/S multiple demonstrates the share price's dependence on antibody test results, with the value holding at 1.60. Alector, Inc. (ALEC) develops treatments for Parkinson's and Alzheimer's diseases by activating microglia. Development relies on a staff of leading researchers with access to cutting-edge laboratories. Capital stability ensures security during the prolonged wait for clinical data.
Alector, Inc. (ALEC) - rincian metrik lan laporan keuangan
- rega saham lan konsensus proyeksi valuasi:
- statistik kapitalisasi pasar:
- indikator kapitalisasi buku:
- statistik kawajiban utang lan likuiditas:
Rasio Total Utang marang Ekuitas Alector, Inc.|ALEC - Rasio utang jangka dawa marang ekuitas|Koefisien utang jangka cendhak marang modal alector.com|ALEC - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku Alector Therapeutics|ALEC - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Alector|Likuiditas darurat alector.com
- data bathi resik lan rasio valuasi:
ALEC - Bathi resik|Bathi mangsa ngarep Alector, Inc.|ALEC - Rasio rega marang bathi|Rasio rega marang bathi mangsa ngarep alector.com|ALEC - Pangali PEG|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Alector Therapeutics|ALEC - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben saham (EPS TTM) Alector|ALEC - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi saben siji saham taun-ka-taun sajrone 12 wulan pungkasan alector.com|ALEC - Wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham ing taun ngarep Alector, Inc.
- data total pendapatan lan volume dodolan:
Analisis umum perusahaan:ALEC Alector Inc.
The P/S ratio compares market capitalization to annual revenue, allowing for an assessment of business value relative to its ability to generate income. By analyzing historical P/S trends, an investor can identify whether an asset is overbought, which is critical for Alector, Inc. (ALEC), as its valuation is based on strong community confidence in its innovative immunotherapy methods for Alzheimer's disease.
Pesaing Alector, Inc.
BIIB (biogen.com) - Rasio kapitalisasi pasar marang pendapatan|Neurocrine Biosciences, Inc. - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan RGC|Axsome Therapeutics Inc - Multiplikator P/S|Koefisien rega marang pendapatan ACADIA Corp ACAD|Xenon Pharmaceuticals (XENE) - Rasio rega marang pendapatan|Rasio kapitalisasi marang pendapatan VKTX|SUPN (Supernus) - Multiplikator P/S|Kapitalisasi marang pendapatan Catalyst Pharma (CPRX)|Kapitalisasi marang pendapatan DNLI (Denali Therapeutics Inc)|Koefisien rega marang pendapatan Harmony Corp|Multiplikator P/S BHVN (Biohaven Ltd.)|Multiplikator P/S amylyx.com AMLX|TRVI - Rasio rega marang pendapatan|PRAX: Rasio rega marang pendapatan|AVXL: Multiplikator P/S|Rega marang dodolan CeriBell EEG (CBLL)|PRTA (Prothena Biosciences) - Multiplikator P/S|Kapitalisasi marang pendapatan annexonbio.com (ANNX)|Rasio rega marang pendapatan Omeros Corporation (OMER)|Neurogene Inc - Rasio kapitalisasi marang pendapatan|Multiplikator P/S ACIU (AC Immune Corp)|Voyager Corp (VYGR) - Rega marang dodolan|NMRA: Kapitalisasi marang pendapatan|SCLX - Multiplikator P/S|Tevogen Bio (TVGN) - Rasio rega marang pendapatan|Alpha Cognition Inc. - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Cognition Therapeutics, Inc.|Rega marang dodolan Inhibikase Pharma IKT|Multiplikator P/S SAVA|Multiplikator P/S assertiotx.com (ASRT)|Rasio rega marang pendapatan Coya Therapeutics COYA|VistaGen Therapeutics, Inc. - Rasio rega marang pendapatan|Ovid Rx - Multiplikator P/S|Rega marang dodolan Acumen Pharmaceuticals, Inc|CRVO: Multiplikator P/S|Kapitalisasi marang pendapatan Alterity Therapeutics Limited|Kapitalisasi marang pendapatan CLNN|PEPG (PepGen Corp) - Kapitalisasi marang volume dodolan|Rasio rega marang pendapatan Jupiter Neurosciences (JUNS)|RLMD - Rega marang dodolan|Rasio rega marang pendapatan Annovis Bio, Inc. ANVS|Rasio kapitalisasi pasar marang pendapatan GRCE|AIFF: Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan KLTO (Klotho Neurosciences Inc)|NRSN: Multiplikator P/S|RVPH - Koefisien rega marang pendapatan|Rasio rega marang pendapatan MetaVia Inc.|Rasio kapitalisasi marang pendapatan NRXS (neuraxis.com)|Multiplikator P/S HSDT|Kapitalisasi marang pendapatan passagebio.com PASG|Neuphoria Therapeutics - Kapitalisasi marang pendapatan|Koefisien rega marang pendapatan Minerva (NERV)|Athira Pharma, Inc. - Multiplikator P/S|ADXN - Multiplikator P/S|alzamend.com (ALZN) - Rasio rega marang pendapatan|CYCN (Cyclerion Therapeutics, Inc.) - Rasio rega marang pendapatan|PTIX (Protagenic Therapeutics Inc.) - Multiplikator P/S|Rega marang dodolan Pasithea KTTA|Multiplikator P/S CRGT|Kapitalisasi marang pendapatan avenuetx.com ATXI|Rasio rega marang pendapatan BrainStorm Cell Therapeutics BCLI|CARA: Rasio kapitalisasi marang pendapatan|Chromocell Therapeutics Corporation - Multiplikator P/S|Rega marang dodolan Eliem Therapeutics|ITCI (intracellulartherapies.com) - Kapitalisasi marang pendapatan|longboardpharma.com (LBPH) - Multiplikator P/S|Rasio rega marang pendapatan Marinus Pharmaceuticals, Inc.|NKGN: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan NeuroBo (NRBO)|SAGE - Rega marang dodolan|Multiplikator P/S SNPX (Synaptogenix, Inc.)|Multiplikator P/S trevena.com TRVN|VIGL - Rasio rega marang pendapatan|WENA: Rasio rega marang pendapatan|CERE: Multiplikator P/S
